Adding Zytiga, Prednisone to ADT Improves Outcomes for Newly Diagnosed, High-risk Metastatic Prostate Cancer Patients

Adding Zytiga, Prednisone to ADT Improves Outcomes for Newly Diagnosed, High-risk Metastatic Prostate Cancer Patients
Newly diagnosed men with high-risk metastatic hormone-naive prostate cancer (mHNPC) lived significantly healthier, longer lives when doctors added Zytiga (abiraterone acetate) and prednisone to their androgen deprivation therapy (ADT), according to results from the Phase 3 LATITUDE trial. The trial (NCT01715285), designed by Belgian pharmaceutical giant Janssen, assessed the safety and effectiveness of the triple combination compared to

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *